|
業務類別
|
Biotechnology |
|
業務概覽
|
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology. |
| 公司地址
| 11 Hurley Street, Cambridge, MA, USA, 02141 |
| 電話號碼
| +1 617 401-9000 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.editasmedicine.com |
| 員工數量
| 246 |
| Ms. Amy Parison |
Senior Vice President, Chief Financial Officer and Treasurer |
-- |
20/03/2025 |
| Dr. Linda C. Burkly, PhD |
Executive Vice President and Chief Scientific Officer |
-- |
15/04/2025 |
| Dr. Gilmore O’Neill, M.B. |
Director, Chief Executive Officer and President |
美元 667.10K |
15/04/2025 |
|
|
| Dr. David T. Scadden, M.D. |
Independent Director |
15/04/2025 |
| Mr. Andrew J. Hirsch |
Independent Director |
15/04/2025 |
| Dr. Gilmore O’Neill, M.B. |
Director, Chief Executive Officer and President |
15/04/2025 |
| Dr. Jessica Hopfield, PhD |
Chairman of the board |
15/04/2025 |
| Ms. Bernadette M. Connaughton |
Independent Director |
15/04/2025 |
| Dr. Elliott M. Levy, M.D. |
Independent Director |
15/04/2025 |
|
|
|
|
